4//SEC Filing
Wissel Janne LT 4
Accession 0001232524-10-000025
CIK 0001232524other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 8:12 PM ET
Size
9.5 KB
Accession
0001232524-10-000025
Insider Transaction Report
Form 4
Wissel Janne LT
SVP, Chief Regulatory Officer
Transactions
- Exercise/Conversion
Common Stock
2010-11-18$1.25/sh+46,663$58,329→ 152,493 total - Sale
Common Stock
2010-11-18$15.05/sh−46,663$702,278→ 105,830 total - Exercise/Conversion
Option (right to buy)
2010-11-18−46,663→ 33,337 totalExercise: $1.25Exp: 2019-01-20→ Common Stock (46,663 underlying)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.35, inclusive.
- [F2]The reporting person undertakes to provide to Jazz Pharmaceuticals, Inc., any security holder of Jazz Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F3]The options represented are vesting over three years measured from the vesting commencement date, January 21, 2009, with 1/3rd vesting on the first anniversary of the vesting commencment date and the remainder vesting in 24 equal monthly installments thereafter. On 11/18/2010, the Transaction Date, options representing 46,663 shares were excercisable.
Documents
Issuer
JAZZ PHARMACEUTICALS INC
CIK 0001232524
Entity typeother
Related Parties
1- filerCIK 0001397268
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 8:12 PM ET
- Size
- 9.5 KB